Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.12 -0.20 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch ↗
Via Stocktwits
Topics Government Stocks
News headline image
Sarepta Therapeutics Inc (NASDAQ:SRPT) Surpasses Q2 2025 Estimates with Strong ELEVIDYS Performance ↗
Sarepta Therapeutics (SRPT) surpasses Q2 2025 estimates with strong ELEVIDYS sales and Roche milestone payments, driving revenue growth and investor optimism. 
Via Chartmill
News headline image
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Sarepta Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Contact Levi &amp; Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank? ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
News headline image
Levi & Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi &amp; Korsinsky Reminds Sarepta Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 25, 2025 - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Contact Levi &amp; Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Trump Overrode RFK Jr. And Makary To Remove FDA Biologics Chief Amid Sarepta Drug Controversy: Report ↗
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics. 
Via Stocktwits
Topics Death ETFs Government
News headline image
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
REPL Stock Nearly Doubled In Value Today: What's Going On? ↗
Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 
Via Stocktwits
News headline image
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
News headline image
Investors Who Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi &amp; Korsinsky About Pending Class Action - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.